Etern Therapeutics – An innovative precision oncology company focused on developing novel small molecule drugs to inhibit “undruggable targets”

Who We Are

ETERN is an innovative biotech company focused on the research and development of small molecule drugs targeting protein liquid-liquid phase separation.

“Undruggable” Targets

LLPS Technology Platform

ETERN has pioneered a state-of-the-art protein liquid-liquid phase separation technology platform that seamlessly integrates AI-assisted phase separation target discovery, high-throughput and high-content drug screening, and drug optimization techniques. The development of small-molecule drugs that effectively regulate protein liquid-liquid phase separation holds immense promise in paving the way for novel therapeutic modalities against a diverse range of challenging targets that are yet to be addressed by conventional drug discovery.